The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Clinuvel Pharmaceuticals volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Most technical analysis of Clinuvel Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Clinuvel from various momentum indicators to cycle indicators. When you analyze Clinuvel charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. The company was founded in 1987 and is headquartered in Melbourne, Australia. Clinuvel Pharm operates under Biotechnology classification in the United States and is traded on OTC Exchange. This overview emphasizes how Clinuvel Pharmaceuticals compares to peers on valuation quality and operating consistency. Current metrics include P/E of 34.88, P/B of 8.27, profit margin of 31.55%. Clinuvel Pharmaceuticals has a market cap of 835.03 M, P/E of 34.88, ROE of 18.62%.
Methodology
Unless otherwise specified, financial data for Clinuvel Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Clinuvel (USA Stocks:CLVLF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Clinuvel Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Tracking Clinuvel Pharmaceuticals inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.